Pharmaniaga Gears up for Strategic Growth

Pharmaniaga Berhad is all geared up for business expansion bolstered by its strong performance in the financial year ended 31 December 2021.

The Group today announced that it has posted its highest ever profit after taxation (PAT) of RM172 million for 2021, increased by over sixfold from RM26 million in FY2020.

Pharmaniaga declared a fourth interim dividend of 5.0 sen per share, which will be paid on 5 April 2022 to shareholders on the register as at 8 March 2022. After adjusting for the four-for-one bonus issue completed in July 2021, the total dividend per share in respect of FY2021 amounted to 9.3 sen. This gives a dividend yield of 13%, based on the closing price of RM0.74 as at 31 December 2021.

The improved bottom line came on the back of a 77% surge in revenue to RM4.8 billion from RM2.7 billion previously. The surge was largely due to the supply Sinovac COVID-19 vaccine to the Ministry of Health (MOH) and the private sector, followed by higher contributions from the Group’s concession, non-concession and Indonesian operations.

The solid performance has opened up more opportunities for the Group to capture new markets both locally and regionally, while remain focused on expanding its offerings as well as diversifying its portfolio to generate new revenue streams for the business.

“With the current capabilities that we have, we intend to supply the vaccine to countries in this region. Myanmar was the first country that we have supplied 30,000 doses, en route to other ASEAN countries,” Datuk Zulkarnain Md Eusope, Pharmaniaga Group Managing Director said.

“Apart from that, we will continue to place emphasis on the research and development of biopharmaceuticals, vaccines and insulins to bolster our product portfolio. We have a large and capable R&D team to formulate our own generic pharmaceutical products,
allowing Pharmaniaga to capture new markets,” he added.

“Besides that, we have inked a Memorandum of Collaboration with Malaysia Healthcare Travel Council in November last year to supply and distribute Hepatitis C drug to the designated hospitals and clinics, which will provide another source of recurring income,” he said.

“Pharmaniaga will continue efforts to expand our presence in ASEAN countries of almost 700 million population, with our products. Our Regulatory Affairs team will engage with the regulatory bodies of these countries as part of our mission to register more of our products there,” he added.

Datuk Zulkarnain said the Group will establish Biopharma Division to focus on the development, production and distribution of biopharmaceutical products to the regional, MENA (Middle East & Northern African) and African countries.

Previous articleFTSE BM KLCI Traded Mixed
Next articleHibiscus Petroleum announced PAT Of RM48.5 M With 843,598 barrels Of Oil Sold For The Quarter

LEAVE A REPLY

Please enter your comment!
Please enter your name here